FLOW SUMMARY

Market sentiment for AnaptysBio is currently mixed, with a speculative BULLISH bias in options. The Put/Call Ratio at 0.56, with 113 calls versus 63 puts, indicates a dominance of bullish option positions, suggesting risk appetite and an offensive stance from market participants. However, institutional activity in dark pools remains subdued, with an OTC volume of 218,858 shares and negligible notional value over the past week, which tempers speculative enthusiasm. Aggregated flows therefore reveal a MIXED bias, with speculative interest in options but an absence of significant institutional engagement in OTC.

TECHNICAL AND VOLUMETRIC STRUCTURE

The ANAB stock is currently trading at $55.93, showing an intraday variation of +1.32% after recent volatility saw the price reach a peak of +2.12%. Over the last three days, the stock exhibited slight selling pressure before this intraday rebound, with closing prices at $54.99 and $54.77. Today's volume is notably low, representing only 9% of its monthly average, indicating a lack of strong conviction behind the current move. Technically, the price is above its 20-day SMA at $55.34 and well above its 200-day SMA at $43.05, signaling a BULLISH underlying trend. However, the RSI(14) at 66.00 is elevated, suggesting potentially exhausted technical momentum and a late entry. In the medium term, the 20-day performance is negative at -15.8%, while the 5-day performance is positive at +4.8%. The stock is positioned at 73% of its 52-week range, with a distance of +29.4% from the 6-month resistance at $72.36. The key 1-month support is at $49.71, and the 1-month resistance is at $70.91.

SCENARIOS & CATALYSTS

Over the primary horizon (medium term, 20-60 days):

Base Scenario (BULLISH, 60% probability): ANAB could experience a significant revaluation if upcoming financial results confirm solid royalty revenue potential, offsetting spin-off related volatility. The analyst consensus, with an average target of $87.09 (+55.7%), anchors this potential. A broad BULL market regime (S&P 500, Nasdaq 100, CAC 40) provides a favorable risk environment. Confirmation of effective spin-off management and clear communication on future strategy would be key catalysts. * Catalysts: Publication of financial results exceeding expectations, positive announcements regarding post-spin-off strategy, favorable market sentiment for biotech.

Bullish Scenario (25% probability): A major positive surprise in the results, particularly regarding royalty revenues or a favorable clarification of the post-spin-off structure, could trigger a rapid rally, propelling the stock towards the upper end of the consensus range ($140.00). Strong institutional accumulation post-results, visible through increased OTC volumes, would validate this scenario. * Catalysts: Announcement of new strategic partnerships, unexpected success in clinical trials, share buybacks or special dividends.

Bearish Scenario (15% probability): Disappointing results, spin-off management perceived as unfavorable, or a deterioration of the macroeconomic backdrop (despite the current BULL regime) could lead to a correction. Geopolitical (78/100), energy (82/100), and monetary (75/100) risks remain high, potentially weighing on risk assets. A break below the support at $49.71 would invalidate the short-term bullish scenario. * Catalysts: Financial results below expectations, increased uncertainties surrounding the spin-off, deterioration of overall macroeconomic sentiment.

AEGIS VERDICT

In a BULL regime (SPY > MA50 > MA200), this BULLISH signal on ANAB is based on the potential for post-results revaluation and the high analyst consensus. Macro risk remains MODERATE-HIGH due to geopolitical, energy, and monetary tensions, justifying prudent sizing. The signal triggers on a daily close above $56.50 with volume exceeding the average of the last 20 days. The first target (TP1) is set at $70.00 for partial profit-taking, with a final target (TP2) at $87.00. The stop-loss is positioned at $49.70. Recommended sizing: Reduced position (0.5x).